The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 20, 2022

Filed:

Sep. 30, 2019
Applicant:

Celgene Corporation, Summit, NJ (US);

Inventors:

Michael D. Amatangelo, Madison, NJ (US);

Chad Bjorklund, Summit, NJ (US);

Anjan Thakurta, Basking Ridge, NJ (US);

Xiankang Hong, Bridgewater, NJ (US);

Mariana Cota, Summit, NJ (US);

Assignee:

CELGENE CORPORATION, Summit, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/45 (2006.01); A61K 47/68 (2017.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/45 (2013.01); A61K 47/6849 (2017.08); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61K 9/0019 (2013.01);
Abstract

Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.


Find Patent Forward Citations

Loading…